5,5'-(1H-isoindole-1,3(2H)-diylidene)dibarbituric acid

Repeated dose toxicity: inhalation

Administrative data

Endpoint:

short-term repeated dose toxicity: inhalation

Type of information:

experimental study

Adequacy of study:

key study

Study period:

Nov 2021 - May 2022

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2022

Materials and methods

Principles of method if other than guideline:

5-day dust inhalation study in rats (with bronchoalveolar lavage, 3 weeks recovery period)

GLP compliance:

yes (incl. QA statement)

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

5,5'-(1H-isoindole-1,3(2H)-diylidene)dibarbituric acid

EC Number:

253-256-2

EC Name:

5,5'-(1H-isoindole-1,3(2H)-diylidene)dibarbituric acid

Cas Number:

36888-99-0

Molecular formula:

C16H9N5O6

IUPAC Name:

5,5'-(1H-isoindole-1,3(2H)-diylidene)dipyrimidine-2,4,6(1H,3H,5H)-trione

Test material form:

solid: nanoform, no surface treatment

Details on test material:

Name of test substance: Pigment Yellow 139
Expiry date: 20 Jul 2030
Chemical name: 5,5'-(1H-isoindole-1,3(2H)-diylidene)dibarbituric acid
Physical state/appearance: Solid/orange
Storage conditions: Room temperature
Batch 200012P040

TEM: D50 = 55.8 nm (D10 = 24.6 and D90 = 195.2)
Aspect ratio: 1.9 : 1
shape: spherical
TEM: 19m2/g
Supplier: Sun Chemical Colors & Effects GmbH

Specific details on test material used for the study:

Pigment Yellow 139
Batch 200012P040
purity > 99%

Test animals

Species:

rat

Strain:

Wistar

Sex:

male

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH; 97633 Sulzfeld
- Age at study initiation: about 7 weeks (when supplied)
- Weight at study initiation (means):ca 255g
- Housing: The rats were housed together (up to 5 animals per cage) in Polysulfon cages (H-Temp [P SU]) supplied by TECNIPLAST, Hohenpeißenberg, Germany (floor area about 2065 cm2). Bedding in
the Polycarbonate cages were Type Lignocel fibres, dust-free bedding, supplied by SSNIFF, Soest,
Germany. Dust-free wooden bedding was used in this study. For enrichment wooden gnawing blocks
(Typ NGM E-022), supplied by Abedd Lab. and Vet. Service GmbH, Vienna, Austria, were added.
- Diet: Mouse/rat laboratory diet “GLP”, 10 mm pellets (Provimi Kliba SA, Kaiseraugst, Basel Switze rland), ad libitum.
- Water: Tap water, ad libitum

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24
- Humidity (%) 45 - 65
- Air changes (per hr): 15
Photoperiod (hrs dark / hrs light):: 12h/12h

Administration / exposure

Route of administration:

inhalation: dust

Type of inhalation exposure:

nose/head only

Vehicle:

clean air

Mass median aerodynamic diameter (MMAD):

>= 0.82 - <= 1.28 µm

Geometric standard deviation (GSD):

3.5

Remarks on MMAD:

MMAD (cascade impactor): between 0.82 and 1.28 µm with GSDs between 3.18 and 4.45. The calculated mass fractions of particles below 3 µm aerodynamic size is greater than 75 %. Thus, the aerosols were highly respirable for rats and a very high proportion of the aerosol particles reached the lungs. SMPS showed different geometric mean concentration than those measured by cascade impactor measurement. Major reason is that this geometric mean referred to count distribution, while cascade impactor measurement measured mass-based aerodynamic diameter. The geometric mean count diameters were between 289 nm and 304 nm.

Details on inhalation exposure:

For each concentration the dust aerosol was generated with the dust generator and compressed air inside a mixing stage, mixed with conditioned air, and passed via the cyclonic separator and glass tube into the inhalation system

GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Generator systems: Solid particle generators (brush-generator), Aerosol mixing tube (Stainless steel), Glass cyclonic separators
- Generation procedure: The test substance was used unchanged. By means of dust generators the substance to be tested is generated into dust aerosols using compressed air in a mixing stage, mixed
with conditioned air and passed into the inhalation systems via cyclonic separators. For each concentration, a solid particle generator (brush-generator) wias used for generating the dust. The con
centration was adjusted by varying the piston feed and by varying the brush rotation. For each concentration the dust aerosol was generated with the dust generator and compressed air inside a mixing stage mixed with conditioned dilution air and passed via the cyclonic separator into the inhalation system.

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

The concentrations of the inhalation atmospheres in test groups 1 - 3 were analyzed by gravimetry. This method was applicable because the test item possessed extremely low vapor pressure. Daily means were calculated based on 3 measured samples per concentration and exposure. From the daily mean values of each concentration, mean concentrations and standard deviations for the entire study were derived.In these groups, the constancy of concentrations in each chamber was continuously monitored using scattered light photometers.

The particle size analysis was carried out with a cascade impactor with the following equipment:
• Stack sampler Marple 298 (New Star Environmental, Inc., Roswell, Georgia 30075, USA)
• Vacuum compressed air pump (Millipore Corporation, Billerica, MA 01821, USA)
• Limiting orifice 3 L/min (Millipore Corporation, Billerica, MA 01821, USA)
• Sampling probe internal diameter 6.9 mm
• Balance Sartorius MSA 6.6S-000-DF (Sartorius AG, Göttingen, Germany)
Sampling for particle size analyses:Pre-weighed metal collecting discs and a backup particle filter were placed into the cascade impactor and two samples were taken in each concentration at a sampling velocity of 1.25 m/sec. from the breathing zones of the animals.
The amount of dust deposited by each stage in mg was calculated from the difference between the weight of the filter/metal collecting disc and backup filter before and after sampling.The deposits in the probe and the wall losses in the impactor were also determined as difference of the total mass increase of the impactor and the sum of masses on the collecting discs and backup filter.

To determine the particle size distribution in the submicrometer range, each test atmosphere was measured with the Scanning Mobility Particle Sizer (SMPS; Grimm Aerosol Technik GmbH& Co KG, Ainring, Germany). The SMPS system comprises an Electrostatic Classifier (Model Vienna U-DMA) which separates the particles into known size fractions, and a Condensation Particle Counter (CPC) which measures particle count concentrations. The DMA was equipped with Am-241 neutralizer. During the exposure period, one measurement per concentration with 10 repeats each were performed.

Real time surveillance of the inhalation atmospheres with scattered light photometers generally proved the constancy of each concentration throughout the daily exposures.
The air flows were constantly maintained in the desired range. An air change of about 65 to 67 times per hour can be calculated by dividing the supply air flow through the volume of each inhalation system. Daily mean relative humidities in the inhalation systems ranged between 33.7 and 49.6 %. Daily mean temperatures in the inhalation systems ranged between 20.6 and 22.1 °C. These values were within guideline recommendations.

Duration of treatment / exposure:

6h for 5 days

Frequency of treatment:

daily

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

5.2 mg/m³ air (analytical)

Remarks:

125548 particles per cm3 (geometric mean diameter 289 nm)

Doses / concentrations 2

Dose / conc.:

20.4 mg/m³ air (analytical)

Remarks:

222788 particles per cm3 (geometric mean diameter 302 nm)

Doses / concentrations 3

Dose / conc.:

59.4 mg/m³ air (analytical)

Remarks:

382709 particles per cm3 (geometric mean diameter 304 nm)

No. of animals per sex per dose:

10 (five for sacrifice after exposure and 5 for sacrifice after recovery)

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale:
- Rationale for animal assignment: random
- Fasting period before blood sampling for clinical bioche Particlesmistry: overnight
- Rationale for selecting satellite groups: Clearance of inert particles by lung macrophages is known to take time
- Post-exposure recovery period in satellite groups: 3 weeks

Positive control:

not applicable

Examinations

Observations and examinations performed and frequency:

A check for moribund or dead animals was carried out twice per day on working days and on Saturday and Sunday 27 and 28 Nov 2021. A check for moribund or dead animals was carried out once per day on weekends and holidays.

The clinical observation was performed on each animal at least three times (before, during and after exposure) on exposure days and once a day during pre-exposure and post exposure observation days. On exposure-free weekends and post exposure observation weekends, no clinical observation was performed. Signs and findings were recorded for each animal.During exposure only a group wise examination was possible.

The animals were weighed prior to the pre-exposure period (study day -5), at the start of the exposure period (study day 0), at the end of the exposure period (study day 4), as well as on the study days 5, 12, 19 and 26.

Food consumption was determined once over the exposure period (study day 0 – study day 4), during the post-exposure period weekly and calculated as mean food consumption in grams per animal and day.The animals were maintained in social-housing cages, with 5 animals per cage, during the whole study period. Therefore, the food consumption was determined cage-wise. The food consumption per animal and day was calculated by dividing food consumption of the day of a respective cage by the 5 animals per cage. As the animals of each test group were housed in only two cages per sex, no statistical evaluation of food consumption is possible

Sacrifice and pathology:

Clinical pathology
In the morning blood was taken from the retro-bulbar venous plexus from fasted animals. The animals were anaesthetized using isoflurane. The blood sampling procedure and subsequent analysis of blood samples were carried out in a randomized sequence (the list of randomization instructions was compiled with a computer).
The assays of blood and serum parameters were performed under internal laboratory quality control conditions with reference controls to assure reliable test results.
The results of clinical pathology examinations were expressed in International System (SI) units. The following parameters of the animals were examined
Clinical chemistry: Alanine aminotransferase, Aspartate aminotransferase, Alkaline phosphatase,-Glutamyltransferase, Inorganic phosphate, Calcium, Urea, Creatinine, Glucose, Total bilirubin, Total protein, Albumin, Globulins,Triglycerides,Cholesterol
Bronchoalveolar lavage fluid (BAL): The animals designated for lung lavage were killed by exsanguination from aorta abdominalis and vena cava under Narcoren® anesthesia. The lung was lavaged by two instillations of physiologic saline.
Parameters and methods of cytological examination in BAL: Total cell count, Macrophages, Polymorphonuclear neutrophils, Lymphocytes, Eosinophils, Monocytes, Epithelial, Gamma−Glutamyltransferase, Protein, Lactate dehydrogenase, Alkaline phosphatase, N-acetyl-Beta-Glucosaminidase
Cytokines in BAL: Rat monocyte chemoattractant protein-1 (rat MCP-1), Rat cytokine-induced neutrophil chemoattractant-1 level (rat CINC-1/IL-8), Rodent osteopontin

Necropsy
The animals were sacrificed under pentobarbital anesthesia by exsanguination from the abdominal aorta and vena cava. Afterwards, the thorax was opened, the right lung lobes werelavaged, whereas the left lung lobe was ligated during lavage. Immediately after lung lavage,
the animals were necropsied and assessed by gross pathology.

The following weights were determined in all animals sacrificed on schedule:
1. Anesthetized animals (terminal body weight)
2. Adrenal glands (fixed)
3. Brain
4. Epididymides
5. Heart
6. Kidneys
7. Liver
8. Lungs
9. Spleen
10. Testes
11. Thymus (fixed)
12. Thyroid glands (with parathyroid glands) (fixed)
All paired organs were weighed together (left and right).

The following organs or tissues were fixed in 4% neutral buffered formaldehyde solution:
1. All gross lesions
2. Adrenal glands
3. Bone marrow (femur)
4. Brain with olfactory bulb
5. Epididymides
6. Esophagus
7. Eyes with optic nerve
8. Heart
9. Kidneys
10. Larynx/pharynx
11. Liver
12. Lungs
13. Lymph nodes (tracheobronchial and mediastinal lymph nodes)
14. Nose (nasal cavity)
15. Seminal vesicles
16. Spinal cord (cervical, thoracic and lumbar cord)
17. Spleen
18. Stomach (forestomach and glandular stomach)
19. Testes
20. Thyroid glands
21. Thymus
22. Trachea
23. Urinary bladder


Extend of histological processing and sub-sequent microscopical examinations in main group animals: all gross lesions, larynx (3 level), lungs, lymph nodes (tracheobronchial, mediastinal), nasal cavity (4 levels), trachea and in recovery group animals: all gross lesions, larynx (3 level), lungs, lymph nodes (tracheobronchial, mediastinal)

Other examinations:

Lung lavage: The animals intended for lung lavage were sacrificed under pentobarbitone anesthesia by exsanguination from the abdominal aorta and vena cava. The right lung will be lavaged in situ with physiological saline, whereas the left lung was ligated during this procedure.

Statistics:

Body weight, body weight change: Comparison of each group with the control group was performed using DUNNETT test (two-sided) for the hypothesis of equal means
Blood parameters: For parameters with bidirectional changes: Non-parametric one-way analysis using KRUSKAL-WALLIS test. If the resulting pvalue was equal or less than 0.05, a pairwise comparison of each dose group with the control group was performed using WILCOXON-test (two-sided) for the hypothesis of equal medians
For parameters with unidirectional changes: Pairwise comparison of each dose group with the control group using the WILCOXON-test (one-sided) for the hypothesis of equal medians
BALF: Pairwise comparison of each dose group with the control group using the WILCOXON-test (one-sided) for the hypothesis of equal medians
Organ weights: Non-parametric one-way analysis using the Kruskal-Wallis test (two-sided). If the resulting p-value was equal to or less than 0.05, a pair-wise comparison of each dose group with the control group was performed using the Wilcoxon test (two-sided) for the hypothesis of equal medians.

Terminal body weight: Comparison of each group with the control group was performed using the Dunnett test (two-sided) for the hypothesis of equal means.

Results and discussion

Results of examinations

Clinical signs:

effects observed, treatment-related

Description (incidence and severity):

Immediately after exposure, one of the ten animals of the test group 1 (5 mg/m³) and all animals of test group 2 (20 mg/m³) and 3 (60 mg/m³) showed test item contaminated fur. In eight of the ten test group 3 animals (60 mg/m³) substance-like discoloration of the nose region was observed before and during exposure on study days 2 and 3. This clinical finding was substance-related, but not adverse because it simply shows the exposure to the solid coloured dusty test substance.

No adverse findings were noted.

Mortality:

no mortality observed

Body weight and weight changes:

no effects observed

Food consumption and compound intake (if feeding study):

no effects observed

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

no effects observed

Ophthalmological findings:

not examined

Haematological findings:

no effects observed

Clinical biochemistry findings:

no effects observed

Endocrine findings:

not examined

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Immunological findings:

not examined

Organ weight findings including organ / body weight ratios:

no effects observed

Description (incidence and severity):

Tables are attached.

Gross pathological findings:

effects observed, treatment-related

Description (incidence and severity):

See Table 4
3 out of 5 animals of test group 2 and all animals of test group 3 of the main group revealed an orange discoloration of the lungs. In addition, a yellow discoloration of the mediastinal and tracheobronchial lymph nodes was observed in 4 out of 5 animals in test group 3. These findings
correlated with the histological presence of particle-containing macrophages in these organs and were considered treatment-related.

After three weeks of recovery, the following was observed:
A yellow to orange discoloration of the lungs, mediastinal and tracheobronchial lymph nodes was present in almost all animals of test group 3 of the recovery group. In test group 2, one animal showed a yellow discoloration of the mediastinal lymph node. These findings correlated with the histological presence of particle-containing macrophages in these organs and were considered treatment-related.

Neuropathological findings:

not examined

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Description (incidence and severity):

See tables 5 and 6

In three animals of test group 1, macrophages in the lungs were present in similar numbers to controls, but contained yellowish to brownish particles in their cytoplasm. In addition, two animals of test group 1 as well as all animals of test groups 2 and 3 showed a dose-dependent minimal to slight increase in the number of macrophages within bronchioli and alveoli (alveolar histiocytosis) with the cells also containing yellowish to brownish particles. In test groups 2 and 3, macrophages were either individually distributed or formed aggregates within bronchioli. The latter showed a minimal increase in cell size, cell number, and/or cell layers of the epithelium (hyperplasia/hypertrophy) in test group 3, only. In addition, particle-containing macrophages were also present in the bronchial-associated lymphoid tissue (BALT) in all treated test groups.
In the larynges at level I, a minimal flattening of epithelial cells, partly associated with an increase in cell layers was multifocally present. The tracheobronchial lymph nodes were chosen exemplarily, similar findings were observed in the mediastinal lymph node. Macrophages containing intracytoplasmic, yellowish to brownish particles were observed in these lymph nodes in minimal to slight numbers.


After three weeks of recovery, the following was observed:
A yellow to orange discoloration of the lungs, mediastinal and tracheobronchial lymph nodes was present in almost all animals of test group 3 of the recovery group. In test group 2, one animal showed a yellow discoloration of the mediastinal lymph node. These findings correlated with the histological presence of particle-containing macrophages in these organs and were considered treatment-related.
In all animals of test group 1, macrophages in the lungs were present in similar numbers to controls, but contained yellowish to brownish particles in their cytoplasm. In all animals of test groups 2 and 3, a dose-dependent minimal to moderate increase in the number of macrophages (alveolar histiocytosis) was observed. The macrophages contained brownish particles and mainly formed aggregates within bronchioli and alveoli. In test group 3, the affected bronchioli showed a minimal increase in cell size, cell number, and/or cell layers of the epithelium (hyperplasia/hypertrophy) and the number of type II pneumocytes was minimally increased in affected alveoli (hyperplasia). Further, lymphocytes and macrophages were also infiltrating the interstitium in minimal numbers in animals of test group 3. In addition, minimal to slight numbers of particle-containing macrophages were found in the bronchial-associated lymphoid tissue in all treated test groups.
The tracheobronchial lymph nodes were chosen exemplarily, similar findings were observed in the mediastinal lymph node. Macrophages containing intracytoplasmic, yellowish to brownish particles were either individually distributed throughout the lymph node or formed aggregates.

Histopathological findings: neoplastic:

not examined

Other effects:

effects observed, treatment-related

Description (incidence and severity):

Bronchoalveolar lavage fluid (BAL) (Table 1-3)
After the administration period, in males of test group 3 (60 mg/m3) total cell counts were marginally, but significantly increased, whereas absolute and relative lymphocyte, monocyte and neutrophil counts were moderately increased (lymphocytes not statistically significantly).
Absolute and relative neutrophil and lymphocyte counts were already marginally, but significantly increased in males of test group 2 (20 mg/m3). Relative macrophage counts were significantly decreased in males of test group 2 and 3. These alterations were regarded as treatment related and adverse.
After the 3-week recovery period absolute and relative lymphocyte, monocyte and neutrophil counts were still marginally increased in males of test group 3 (monocyte counts not statistically significantly) whereas the significantly increased total cell counts among these individuals were regarded as not toxicologically relevant. Relative macrophage counts were also still significantly decreased in BAL of males in test group 3. Neutrophil counts were also significantly increased in BAL of males in test group 1 (5 mg/m3), but this change was not dose dependent and therefore it was regarded as incidental and not treatment related.
After the administration period, in males of test group 3 (60 mg/m3) -glutamyl-transferase (GGT) and alkaline phosphatase (ALP) activities in BAL were slightly but significantly increased. These alterations were regarded as treatment related and adverse. Total protein and -N-acetylglucosaminidase (NAG) activities were only marginally (≤ 2-fold) increased. These increases were regarded as treatment related but non-adverse.
After the recovery period total protein levels as well as GGT, LDH and NAG levels in BAL of males in test group 3 (60 mg/m3) were significantly increased. However, when regarding the absolute values, they were within historical control ranges (males, total protein 2-50 mg/L, GGT 25-57 nkat/L, LDH 0.21-0.65 μkat/L, NAG 18-56 nkat/L). Therefore, these alterations were regarded as incidental and not treatment related.
After the administration period, in males of test group 3 (60 mg/m3) cytokine-induced neutrophil chemoattractant-1 (CINC-1/IL8), monocyte chemoattractant protein-1 (MCP-1) and osteopontin
levels in BAL were significantly increased. These alterations were regarded as treatment related and adverse. CINC-1/IL-8 values were already significantly increased in males of test group 2 (20 mg/m3) but the increase was below 2-fold, and therefore, it was regarded as treatment
related but non-adverse.
After the three-week recovery period in males of test group 3 (60 mg/m3) MCP-1 and osteopontin levels in BAL were still more than 2-fold increased (osteopontin not statistically significantly)
whereas CINC-1/IL-8 levels in males of test groups 1 and 3 (5 and 60 mg/m3) as well as MCP1 values in males of test group 2 (20 mg/m3) were significantly but less than 2-fold increased. Therefore, only CINC-1/IL-8 and osteopontin level increases in males of test group 3 were
regarded as relevant.

Effect levels

1

Dose descriptor:

NOEC

Remarks:

local effects

Effect level:

5.2 mg/m³ air (analytical)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: at 20 mg/m3: Increased absolute and relative neutrophil and lymphocyte and decreased relative macrophage counts in BAL after exposure

2

Dose descriptor:

NOEC

Remarks:

systemic effects

Effect level:

>= 59.4 mg/m³ air (analytical)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: only findings in BALF

Target system / organ toxicity

Critical effects observed:

yes

Lowest effective dose / conc.:

59.4 mg/m³ air (analytical)

System:

respiratory system: upper respiratory tract

Organ:

lungs

Treatment related:

yes

Dose response relationship:

yes

Any other information on results incl. tables

No adverse effect was observed at 5 mg/m³. No systemic effect was observed up to the highest tested concentration of 60 mg/m³. Target organ was the lung. While parameters in lavage fluid were fully reversible within 3 weeks post-exposure period, the histological changes at 60 mg/m³ were not reversible within the 3 -week recovery period.

Table 1: Changes in mean absolute cell counts in BAL (x-fold of concurrent control) on study day 5 (1 day after last exposure) and study days 26 (3 weeks after last exposure). At study day 5, mean of differential cell counts in control group (test group 0) is based on only two individuals due to bad cell quality. Therefore, for these parameters, statistics could not be performed.

	Study day 5			Study day 26
	Gr. 1 5 mg/m3	Gr. 2 20 mg/m3	Gr. 3 60 mg/m3	Gr. 1 5 mg/m3	Gr. 2 20 mg/m3	Gr. 3 60 mg/m3
Total Cells	0.9	0.9	2.2*	1.1	1.0	1.4*
Eosinophils	0.6	1.1	0.7	+	+	+
Lymphocytes	1.6	2.2*	12.7	0.8	1.2	3.4*
Macrophages	0.9	0.8	0.8	1.0	1.0	1.0
Neutrophils	0.3	10.2**	127.9**	4.8*	2.4	13.5**
Monocytes	+	+	+**	0.4	0.7	7.4
Epithelial cells	0.9	0.7	0.0	3.3	0.2	1.5

One-sided Wilcoxon-test: * : p <= 0.05; ** : p <= 0.01

+ increase could not be calculated because of zero activity in controls

Table 2: Changes in mean total protein and enzyme levels in BAL (x-fold of concurrent control) of males on study day 5 (1 day after last exposure) and study day 26 (3 weeks afterlast exposure)

	Study day 5			Study day 26
	Gr. 1 5 mg/m3	Gr. 2 20 mg/m3	Gr. 3 60 mg/m3	Gr. 1 5 mg/m3	Gr. 2 20 mg/m3	Gr. 3 60 mg/m3
Total Protein	0.9	1.1	1.6*	0.9	0.9	1.3*
GGT	1.1	1.3	2.6**	1.0	1.2	1.5**
LDH	1.1	0.9	1.8	1.2	1.1	1.8**
ALP	1.2	1.3*	2.3**	0.8	0.9	1.2
NAG	1.3	1.3	1.6**	1.8	0.9	2.1*

GGT = Gamma-Glutamyl-transferase; LDH = Lactate dehydrogenase; ALP = Alkaline phosphatase; NAG = Beta-N-Acetyl glucosaminidase, One-sided Wilcoxon-test: * : p <= 0.05; ** : p <= 0.01

Table 3: Changes in antigen levels in BAL (x-fold of concurrent control means) of males onstudy day 5 (1 day after last exposure) and study day 26 (3 weeks after last exposure)

	Study day 5			Study day 26
	Gr. 1 5 mg/m3	Gr. 2 20 mg/m3	Gr. 3 60 mg/m3	Gr. 1 5 mg/m3	Gr. 2 20 mg/m3	Gr. 3 60 mg/m3
MCP-1	0.9	1.8	7.2*	1.0	1.6*	4.4**
CINC-1/IL-8	1.1	1.5*	5.0**	1.5*	1.0	1.4*
Osteopontin	0.4	0.6	2.7*	1.2	1.2	2.7

BALF = Broncho-alveolar lavage fluid; CINC-1/IL-8 = cytokine-induced neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1

One-sided Wilcoxon-test: * : p <= 0.05; ** : p <=0.01

Table 4: Gross lesions in the main and recovery group animals

	main group				recovery group
Test group (mg/m³)	0 (0)	1 (5)	2 (20)	3 (60)	0 (0)	1 (5)	2 (20)	3 (60)
No. of animals	5	5	5	5	5	5	5	5
Lungs ·    Discoloration	0	0	3	5	0	0	0	1
Mediastinal lymph node ·    Discoloration	0	0	0	4	0	0	1	4
Tracheobronchial lymph node ·    Discoloration	0	0	0	4	0	0	0	3

Table 5 Histopathology findings in rats of the main group

Lungs	main group
Test group (mg/m³)	0 (0)	1 (5)	2 (20)	3 (60)
No. of animals	5	5	5	5
Hyperplasia/hypertrophy, bronchioli; (multi)focal	0	0	0	5
·    Grade 1	0	0	0	5
Macrophages with particles; (multi)focal	0	3	0	0
·    Grade 1	0	3	0	0
Macrophages with particles; bronchial-associated lymphoid tissue; (multi)focal	0	1	4	5
·    Grade 1	0	1	4	5
Histiocytosis, alveolar, with particles; (multi)focal	0	2	5	5
·    Grade 1	0	2	5	0
·    Grade 2	0	0	0	5
Larynx (level I)	main group
Test group (mg/m³)	0 (0)	1 (5)	2 (20)	3 (60)
No. of animals	5	5	5	5
Epithelial alteration, (multi)focal	2	3	4	4
·    Grade 1	2	3	4	4
Tracheobronchial lymph nodes	main group
Test group (mg/m³)	0 (0)	1 (5)	2 (20)	3 (60)
No. of animals	5	5	5	5
Macrophages with particles; (multi)focal	0	1	3	4
·    Grade 1	0	1	3	3
·    Grade 2	0	0	0	1

Table 6 Histopathology findings after 3 weeks of recovery

Lungs	recovery group
Test group (mg/m³)	0 (0)	1 (5)	2 (20)	3 (60)
No. of animals	5	5	5	5
Hyperplasia/hypertrophy, bronchioli; (multi)focal	0	0	0	5
·    Grade 1	0	0	0	5
Macrophages with particles; (multi)focal	0	5	0	0
·    Grade 1	0	5	0	0
Macrophages with particles; bronchial-associated lymphoid tissue; (multi)focal	0	4	5	5
·    Grade 1	0	4	4	4
·    Grade 2	0	0	1	1
Histiocytosis, alveolar, with particles; (multi)focal	0	0	5	5
·    Grade 1	0	0	2	0
·    Grade 2	0	0	3	1
·    Grade 3	0	0	0	4
Hyperplasia, type ll pneumocytes; (multi)focal	0	0	0	5
·    Grade 1	0	0	0	5
Infiltrate; interstitial; lymphohistiocytic, (multi)focal	0	0	0	5
·    Grade 1	0	0	0	5
Tracheobronchial lymph nodes	recovery group
Test group (mg/m³)	0 (0)	1 (5)	2 (20)	3 (60)
No. of animals	5	5	5	5
Macrophages with particles; (multi)focal	0	3	4	4
·    Grade 1	0	3	4	1
·    Grade 2	0	0	0	3
Macrophage aggregates with particles; (multi)focal	0	0	1	4
·    Grade 1	0	0	1	3
·    Grade 2	0	0	0	1

Applicant's summary and conclusion

Conclusions:

The no observed adverse effect concentration (NOAEC) for local effects was 5 mg/m³ for Pigment Yellow 139. The systemic NOAEC is above 60 mg/m³ (high concentration group).

Executive summary:

The purpose of this study was to determine the pulmonary toxicity in rats using a short-term bioassay including bronchoalveolar lavage with clinico-chemical and cytological evaluation of lavage fluid and pathological examination of the lung. The No Observed Adverse Effect Concentration (NOAEC) after 5 days inhalation exposure to dust of Pigment Yellow 139 was determined. In addition, recovery group animals were examined after an exposure-free period of 3 weeks to detect any reversibility or progression of potential toxic effects.

For this purpose, nine-week-old male Wistar rats (10 rats per concentration group) were nose only exposed to fresh air (control group) or dust of the test substance at concentrations of 5, 20, and 60 mg/m3 (low, mid, and high concentration) for 6 hours per day and 5 days. Body weight, mortality, and clinical observations were determined during the study. One half of the rats was examined at the end of the exposure period, whereas the other half was examined at the end of a 3-week post-exposure period by determining clinical pathology parameters including bronchoalveolar lavage with clinico-chemical and cytological evaluation of lavage fluid, organ weights and all histopathological changes.

The particle size resulted in MMADs between 0.82 and 1.28 µm with GSDs between 3.18 and 4.45. The calculated mass fractions of particles below 3 µm aerodynamic size is greater than 75 %. Thus, the aerosols were highly respirable for rats and a very high proportion of the aerosol particles reached the lungs.

The following substance-relative adverse findings were observed:

Test group 3 (60 mg/m3 ) after exposure (main group)

• Increased total cell counts as well as absolute and relative neutrophil, lymphocyte and monocyte counts in BAL

• Decreased relative macrophage counts in BAL

• Increased gamma-glutamyl-transferase (GGT) and alkaline phosphatase (ALP) activities in BAL

• Increased cytokine-induced neutrophil chemoattractant-1 (CINC-1/IL8), monocyte chemoattractant protein-1 (MCP-1) and osteopontin levels in BAL

• Minimal to slight alveolar histiocytosis with particles

• Minimal hypertrophy/hyperplasia of bronchioli

Test group 3 (60 mg/m3 ) after 3 weeks post-exposure observation period

• Slight to moderate alveolar histiocytosis with particles

• Minimal hypertrophy/hyperplasia of bronchioli

• Minimal type II pneumocyte hyperplasia

• Minimal interstitial lymphohistiocytic infiltrates

Test group 2 (20 mg/m3 ) after exposure (main group)

• Increased absolute and relative neutrophil and lymphocyte counts in BAL

• Decreased relative macrophage counts in BAL

Test group 2 (20 mg/m3 ) after 3 weeks post-exposure observation period

• No adverse effects were observed regarding pathology findings.

Test group 1 (5 mg/m3 ) after exposure (main group)

No treatment-related, adverse effects.

Test group 1 (5 mg/m3 ) after 3 weeks post-exposure observation period

No treatment-related, adverse effects.